MedTrace Logo

A Study of AK146D1 for Injection in the Treatment of Advanced Solid Tumors

NCT06929663 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 48

Last updated 2025-07-17

No results posted yet for this study

Summary

This is an first-in-human, Phase I clinical study aimed at evaluating the safety, tolerability, PK, immunogenicity, and preliminary antitumor efficacy of AK146D1 for injection in advanced solid tumors.

Conditions

Interventions

DRUG

AK146D1 for injection

AK146D1 for injection is an anti-Trop2/Nectin4 bispecific antibody-drug conjugate

Sponsors & Collaborators

Principal Investigators

  • Hui Gan · Austin Health

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-07-02
Primary Completion
2026-11-05
Completion
2027-05-05

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06929663 on ClinicalTrials.gov